Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5872501 | 0.97 | NPC1 (0.40) | NPC1 | |
| SCHEMBL22692805 | 0.97 | NPC1 (0.40) | NPC1 | |
| SCHEMBL8077432 | 0.83 | — | — | |
| SCHEMBL2647634 | 0.80 | ALDH1A1 (0.44) | — | |
| SCHEMBL2647631 | 0.80 | ALDH1A1 (0.44) | — | |
| SCHEMBL24339629 | 0.78 | TSHR (0.31) | — | |
| SCHEMBL10337190 | 0.78 | — | — | |
| SCHEMBL3271892 | 0.78 | MAPK8 (0.34) | — | |
| SCHEMBL408304 | 0.78 | HTR2C (0.35) | — | |
| SCHEMBL15683008 | 0.78 | TSHR (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118156613-A | Electrolyte additive for lithium ion or sodium ion secondary battery and application thereof | 北京大学深圳研究生院 | 2024-06-07 | — | — | CN | claimed |
| CN-115692852-A | Imidazole structure-containing electrolyte additive, electrolyte and lithium ion battery | 中节能万润股份有限公司 | 2023-02-03 | — | — | CN | claimed |
| CN-118156613-A | Electrolyte additive for lithium ion or sodium ion secondary battery and application thereof | 北京大学深圳研究生院 | 2024-06-07 | — | — | CN | disclosed |
| CN-115692852-A | Imidazole structure-containing electrolyte additive, electrolyte and lithium ion battery | 中节能万润股份有限公司 | 2023-02-03 | — | — | CN | disclosed |
| US-10847790-B2 | Functionalised electrochemically active material and method of functionalisation | NEXEON LIMITED (GB) | 2020-11-24 | — | — | US | disclosed |
| US-7605163-B2 | Benzoyl-piperazine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-10-20 | — | — | US | disclosed |
| US-20080119486-A1 | BENZOYL-PIPERAZINE DERIVATIVES | JOLIDON SYNESE | 2008-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119486-A1 | BENZOYL-PIPERAZINE DERIVATIVES | SLC1A2, SLC18A2, SLC6A7 | NPC1 209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.